RedHill Biopharma Launches Phase 2 Clinical Trial for Opaganib/Darolutamide Combination in Advanced Prostate Cancer

Reuters

2025/07/02

RedHill Biopharma Launches Phase 2 Clinical Trial for Opaganib/Darolutamide Combination in Advanced Prostate Cancer

RedHill Biopharma Ltd. has announced the initiation of patient recruitment for a Phase 2 clinical study to evaluate the efficacy of a combination treatment using opaganib and darolutamide in men with metastatic castrate-resistant prostate cancer (mCRPC). This study, sponsored by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd. (ANZUP), is supported by Bayer and the Ramsay Hospital Research Foundation. The study aims to recruit 60 participants across multiple sites in Australia and New Zealand and will use the PCPro™ lipid biomarker test to identify patients with a poor prognosis who are most likely to benefit from the treatment. Led by Professor Lisa Horvath, the study's primary endpoint is improved 12-month radiographic progression-free survival, with several secondary and exploratory endpoints also being evaluated. The results of the study will be presented in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO22154) on July 01, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2548355885"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548355885\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548355885?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-02 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548355885","market":"fut","top_or_hot":-1,"title":"RedHill Biopharma Launches Phase 2 Clinical Trial for Opaganib/Darolutamide Combination in Advanced Prostate Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      RedHill Biopharma Launches Phase 2 Clinical Trial for Opaganib/Darolutamide Combination in Advanced Prostate Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        RedHill Biopharma Ltd. has announced the initiation of patient recruitment for a Phase 2 clinical study to evaluate the efficacy of a combination treatment using opaganib and darolutamide in men with metastatic castrate-resistant prostate cancer (mCRPC). This study, sponsored by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd. (ANZUP), is supported by Bayer and the Ramsay Hospital Research Foundation. The study aims to recruit 60 participants across multiple sites in Australia and New Zealand and will use the PCPro™ lipid biomarker test to identify patients with a poor prognosis who are most likely to benefit from the treatment. Led by Professor Lisa Horvath, the study's primary endpoint is improved 12-month radiographic progression-free survival, with several secondary and exploratory endpoints also being evaluated. The results of the study will be presented in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/RDHL\">Redhill Biopharma Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO22154) on July 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RedHill Biopharma Launches Phase 2 Clinical Trial for Opaganib/Darolutamide Combination in Advanced Prostate Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRedHill Biopharma Launches Phase 2 Clinical Trial for Opaganib/Darolutamide Combination in Advanced Prostate Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-02 00:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      RedHill Biopharma Launches Phase 2 Clinical Trial for Opaganib/Darolutamide Combination in Advanced Prostate Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        RedHill Biopharma Ltd. has announced the initiation of patient recruitment for a Phase 2 clinical study to evaluate the efficacy of a combination treatment using opaganib and darolutamide in men with metastatic castrate-resistant prostate cancer (mCRPC). This study, sponsored by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd. (ANZUP), is supported by Bayer and the Ramsay Hospital Research Foundation. The study aims to recruit 60 participants across multiple sites in Australia and New Zealand and will use the PCPro™ lipid biomarker test to identify patients with a poor prognosis who are most likely to benefit from the treatment. Led by Professor Lisa Horvath, the study's primary endpoint is improved 12-month radiographic progression-free survival, with several secondary and exploratory endpoints also being evaluated. The results of the study will be presented in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/RDHL\">Redhill Biopharma Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO22154) on July 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RDHL","symbol_name":"Redhill Biopharma Ltd","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nNDL82bqVY:1","article_id":"2548355885","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548355885","pubTimestamp":1751385635,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"RedHill Biopharma Ltd. has announced the initiation of patient recruitment for a Phase 2 clinical study to evaluate the efficacy of a combination treatment using opaganib and darolutamide in men with metastatic castrate-resistant prostate cancer . This study, sponsored by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd. , is supported by Bayer and the Ramsay Hospital Research Foundation. The study aims to recruit 60 participants across multiple sites in Australia and New Zealand and will use the PCPro lipid biomarker test to identify patients with a poor prognosis who are most likely to benefit from the treatment. Led by Professor Lisa Horvath, the study's primary endpoint is improved 12-month radiographic progression-free survival, with several secondary and exploratory endpoints also being evaluated. The results of the study will be presented in the future.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RDHL":"Redhill Biopharma Ltd","BK4007":"制药"},"translate_title":"RedHill Biopharma启动Opaganib/Darolutamide联合治疗晚期前列腺癌的2期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RDHL":0.9},"content_text":"RedHill Biopharma Launches Phase 2 Clinical Trial for Opaganib/Darolutamide Combination in Advanced Prostate Cancer\n    \n\n        RedHill Biopharma Ltd. has announced the initiation of patient recruitment for a Phase 2 clinical study to evaluate the efficacy of a combination treatment using opaganib and darolutamide in men with metastatic castrate-resistant prostate cancer (mCRPC). This study, sponsored by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd. (ANZUP), is supported by Bayer and the Ramsay Hospital Research Foundation. The study aims to recruit 60 participants across multiple sites in Australia and New Zealand and will use the PCPro™ lipid biomarker test to identify patients with a poor prognosis who are most likely to benefit from the treatment. Led by Professor Lisa Horvath, the study's primary endpoint is improved 12-month radiographic progression-free survival, with several secondary and exploratory endpoints also being evaluated. The results of the study will be presented in the future.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO22154) on July 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}